97 related articles for article (PubMed ID: 2784711)
1. Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9.
O'Connell MJ; Ritts RA; Moertel CG; Schutt AJ; Sherwin SA
Cancer; 1989 May; 63(10):1998-2004. PubMed ID: 2784711
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM; Weimar W; Tank B; Dekkers-Bijma AM; Marquet RL; Lameris JS; Westbroek DL; Jeekel J
Cancer Immunol Immunother; 1986; 21(1):81-4. PubMed ID: 3632919
[TBL] [Abstract][Full Text] [Related]
3. Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study.
Radice E; Miranda V; Bellone G
Int Immunopharmacol; 2014 Mar; 19(1):66-73. PubMed ID: 24369312
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
Hersey P; Hasic E; MacDonald M; Edwards A; Spurling A; Coates AS; Milton GW; McCarthy WH
Br J Cancer; 1985 Jun; 51(6):815-26. PubMed ID: 3873953
[TBL] [Abstract][Full Text] [Related]
6. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma.
Creagan ET; Loprinzi CL; Ahmann DL; Schaid DJ
Cancer; 1988 Dec; 62(12):2472-4. PubMed ID: 3142675
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
10. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
11. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
[TBL] [Abstract][Full Text] [Related]
13. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
14. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
15. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of recombinant leukocyte alpha 2 interferon in patients with advanced malignancy.
Muss HB; Richards F; Homesley HD; Spurr CL; Rudnick SA; Stuart JJ; Plunkett S; Welander C; Caponera M; White DR
Am J Clin Oncol; 1985 Apr; 8(2):97-107. PubMed ID: 3834792
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of combined intraperitoneal administration of human recombinant interferon-beta and interferon-gamma against intraabdominal carcinomatosis in nude mice.
Kondo H; Tanaka N; Naomoto Y; Orita K
Acta Med Okayama; 1988 Apr; 42(2):69-75. PubMed ID: 3133927
[TBL] [Abstract][Full Text] [Related]
18. The determination of an immunologically active dose of interferon-gamma in patients with melanoma.
Maluish AE; Urba WJ; Longo DL; Overton WR; Coggin D; Crisp ER; Williams R; Sherwin SA; Gordon K; Steis RG
J Clin Oncol; 1988 Mar; 6(3):434-45. PubMed ID: 3127550
[TBL] [Abstract][Full Text] [Related]
19. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.
Krown SE; Mintzer D; Cunningham-Rundles S; Niedzwiecki D; Krim M; Einzig AI; Gabrilove JL; Shurgot B; Gessula J
Cancer Treat Rep; 1987 Jan; 71(1):39-45. PubMed ID: 3791267
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
